Home › Neuroendocrine Tumors › California › Los Angeles
Neuroendocrine Tumors clinical trials in Los Angeles, CA
5 studies for Neuroendocrine Tumors are looking for participants at sites in and around Los Angeles (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
RecruitingPhase 2/3
- Norris Comprehensive Cancer Center, Los Angeles
Project: Every Child for Younger Patients With Cancer
RecruitingObservational study
- Children's Hospital Los Angeles, Los Angeles
- Cedars-Sinai Medical Center, Los Angeles
- Mattel Children's Hospital UCLA, Los Angeles
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
RecruitingPhase 1
- UCLA / Jonsson Comprehensive Cancer Center, Los Angeles
Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
Recruiting
- Cedars-Sinai Medical Center, Los Angeles
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RecruitingPhase 1/2
- University of Southern California, Los Angeles
Neuroendocrine Tumors trials in other cities
- Philadelphia, PA11 studies
- Washington, DC11 studies
- Rochester, MN9 studies
- Houston, TX8 studies
- Chicago, IL7 studies
- Columbus, OH7 studies
- St. Louis, MO7 studies
- Detroit, MI7 studies
- Salt Lake City, UT7 studies
- Cleveland, OH7 studies
- Dallas, TX6 studies
- Charlottesville, VA6 studies
Other studies in Los Angeles
- Non-Small Cell Lung Cancer87 studies
- Cancer (all types)74 studies
- Breast Cancer73 studies
- Prostate Cancer61 studies
- Colorectal Cancer59 studies
- Metastatic Cancer57 studies
- Ovarian Cancer50 studies
- Lung Cancer45 studies
- Head and Neck Squamous Cell Carcinoma42 studies
- Pancreatic Cancer35 studies
- Endometrial Cancer34 studies
- Melanoma34 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.